Radiolabeling of avidin with very high specific activity for internal radiation therapy of intraperitoneally disseminated tumors.
暂无分享,去创建一个
M. Brechbiel | Hisataka Kobayashi | T. Saga | J. Konishi | T. Higashi | M. Mamede | T. Ishimori | N. Sato
[1] R. L. Juliano,et al. PAMAM Dendrimers as Delivery Agents for Antisense Oligonucleotides , 2004, Pharmaceutical Research.
[2] M. Brechbiel,et al. Micro‐MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer‐based MR contrast agents , 2001, Journal of magnetic resonance imaging : JMRI.
[3] P. Sugarbaker. Review of a personal experience in the management of carcinomatosis and sarcomatosis. , 2001, Japanese journal of clinical oncology.
[4] K Togashi,et al. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] M. Brechbiel,et al. Avidin-dendrimer-(1B4M-Gd)(254): a tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI. , 2001, Bioconjugate chemistry.
[6] M. Béhé,et al. Therapeutic advantages of Auger electron- over β-emitting radiometals or radioiodine when conjugated to internalizing antibodies , 2000, European Journal of Nuclear Medicine.
[7] Martin W. Brechbiel,et al. Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity , 2000, European Journal of Nuclear Medicine.
[8] J. Humm,et al. Dosimetry of Auger-Electron-Emitting Radionuclides , 2000 .
[9] Radioimmunotherapy of human glioma xenografts in nude mice by indium-111 labelled internalising monoclonal antibody. , 1999, European journal of cancer.
[10] G. Griffiths,et al. Cytotoxicity with Auger electron‐emitting radionuclides delivered by antibodies , 1999, International journal of cancer.
[11] S. Rubin,et al. Primary peritoneal carcinoma: a review of the literature. , 1999, Obstetrical & gynecological survey.
[12] J. Murray,et al. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] H. Sakahara,et al. The relationship of glycosylation and isoelectric point with tumor accumulation of avidin. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] M. Brechbiel,et al. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. , 1999, Bioconjugate chemistry.
[15] M. Cremonesi,et al. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. , 1998, British Journal of Cancer.
[16] D. Goldenberg,et al. Therapeutic efficacy and dose‐limiting toxicity of auger‐electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: Evaluation of 125I‐ vs. 131I‐labeled CO17‐1A in a human colorectal cancer model , 1998, International journal of cancer.
[17] 姚正生. Avidin targeting of intraperitoneal tumor xenografts(腹腔内移植腫瘍のアビジンによるターゲティング) , 1998 .
[18] R. Juliano,et al. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. , 1997, Journal of pharmaceutical sciences.
[19] H. Sakahara,et al. Intravenous avidin chase improved localization of radiolabeled streptavidin in intraperitoneal xenograft pretargeted with biotinylated antibody. , 1997, Nuclear medicine and biology.
[20] J. Baker,et al. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. , 1996, Nucleic acids research.
[21] J. Baker,et al. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[22] S. Spencer,et al. Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] S. Adelstein,et al. The effects of indium-111 decay on pBR322 DNA. , 1994, Radiation research.
[24] F. Mangili,et al. Radioimmunoguided surgery using iodine-125-labeled biotinylated monoclonal antibodies and cold avidin. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] J. Humm,et al. Dosimetry of Auger-electron-emitting radionuclides: report no. 3 of AAPM Nuclear Medicine Task Group No. 6. , 1994, Medical physics.
[26] H. Sakahara,et al. Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] J. Fréchet,et al. Functional polymers and dendrimers: reactivity, molecular architecture, and interfacial energy. , 1994, Science.
[28] Martin W. Brechbiel,et al. Metal-chelate-dendrimer-antibody constructs for use in radioimmunotherapy and imaging , 1994 .
[29] R. Barth,et al. Boron neutron capture therapy of primary and metastatic brain tumors , 1994, Molecular and chemical neuropathology.
[30] R. Howell,et al. Radiation spectra for Auger-electron emitting radionuclides: report No. 2 of AAPM Nuclear Medicine Task Group No. 6. , 1992, Medical physics.
[31] V. Zurawski,et al. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. , 1992, Gynecologic oncology.
[32] L. Lopalco,et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. , 1991, Cancer research.
[33] W. Mccaughey,et al. Pathology of the peritoneum: a review of selected topics. , 1991, Seminars in diagnostic pathology.
[34] William A. Goddard,et al. Starburst Dendrimers: Molecular‐Level Control of Size, Shape, Surface Chemistry, Topology, and Flexibility from Atoms to Macroscopic Matter , 1990 .
[35] J. Mclean,et al. The radiation dose to cells in vitro from intracellular indium-111. , 1989, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[36] J. Mclean,et al. The Auger electron dosimetry of indium-111 in mammalian cells in vitro. , 1989, Radiation research.
[37] M Monsigny,et al. Endogenous Lectins and Drug Targeting , 1988, Annals of the New York Academy of Sciences.
[38] R. Lotan,et al. Lectins in Cancer Cells , 1988, Annals of the New York Academy of Sciences.
[39] J. Gershoni,et al. Biotin binding to avidin. Oligosaccharide side chain not required for ligand association. , 1987, The Biochemical journal.
[40] J. Beatty,et al. Therapy of peritoneal carcinomatosis of human colon cancer xenografts with yttrium 90-labeled anti-carcinoembryonic antigen antibody ZCE025. , 1987, Archives of surgery.
[41] R. Lotan,et al. Transformation‐related changes in the expression of endogenous cell lectins , 1987, International journal of cancer.
[42] H. Gabius,et al. Endogenous tumor lectins: overview and perspectives. , 1986, Anticancer research.
[43] P. Stahl,et al. Isolation and characterization of a mannose/N-acetylglucosamine/fucose-binding protein from rat liver. , 1981, The Biochemical journal.